Authors
Latest:
Future Treatment Approaches for HCCClosing out their discussion on the management of hepatocellular carcinoma, panelists discuss future novel therapies that may impact the treatment landscape.
Latest:
Boland Discusses Melanoma Treatment UpdatesGenevieve Boland, MD, PhD, discusses the latest updates to the melanoma treatment landscape.
Latest:
Ra-223 Demonstrates Safety, Efficacy in Managing Bone Metastases in Prostate CancerPatients diagnosed with bone metastatic, castration-resistant prostate cancer and treated with radium-223 showed lower incidences of treatment-related adverse events or treatment discontinuation, particularly when used in the front-line setting.
Latest:
Neoadjuvant Blockade Demonstrates Significant Clinical Activity in UPSChristina L. Roland, MD, PhD, discusses the preliminary results of neoadjuvant checkpoint blockade—nivolumab or nivolumab plus ipilimumab—in patients with surgically resectable undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma.
Latest:
Examining Changes in the Multiple Myeloma Treatment LandscapeJeffrey R. Schriber, MD, FRCP, discusses some of the available treatment options for patients with multiple myeloma and how the treatment landscape has evolved over time.
Latest:
FDA-Approved Oral Hypomethylating Agent Regimen Excites MDS LandscapeGuillermo Garcia-Manero, MD, discusses how the recently approved combination regimen of decitabine and cedazuridine fits into the treatment landscape for patients with myelodysplastic syndromes.
Latest:
10 Years in CLL: Top Advances From 2012-2022The past decade has seen the FDA approve a handful of new targeted therapies for chronic lymphocytic leukemia that are prompting a move toward chemotherapy-free treatment of the disease.
Latest:
Pembrolizumab Plus Chemotherapy Show Efficacy for TNBC in KEYNOTE-355Javier Cortes, MD, PhD, discusses the data from the phase 3 KEYNOTE-355 trial of pembrolizumab and chemotherapy versus placebo and chemotherapy for previously untreated patients with locally recurrent inoperable or metastatic triple-negative breast cancer.
Latest:
Differentiating Pseudoprogression From Hyperprogression in Patients Treated With ImmunotherapiesAdvances in the field have also led to the recognition of other clinical challenges, including unforeseen observations and complications associated with choosing the sequencing of appropriate therapeutic interventions as well as the management of drug-related complications.
Latest:
Ibrutinib Plus Venetoclax May Be an Effective Treatment for Previously Untreated WMFast and durable response were seen in patients with Waldenström Macroglobulinemia who received the combination of ibrutinib and venetoclax.
Latest:
Discussing the FOHAIC-1 Study for Patients With HCCMing Zhao, MD, explains the background of the FOHAIC-1 study.
Latest:
Breast Cancer Awareness Month: What to Know for Different Types of Breast CancerFor Breast Cancer Awareness Month Kristina Mirabeau-Beale, mD, MPH, and Bridget Koontz, MD, discuss the different types of breast cancer that clinicians need to be aware of.
Latest:
Case 3: Role of Preoperative Endocrine Therapy in HR+ High-Risk Breast CancerHeather McArthur, MD; Massimo Cristofanilli, MD, FACP; Sunil Badve, MD, FRCPath; and Joyce O’Shaughnessy, MD, comment on the role of preoperative endocrine therapy in HR-positive high-risk breast cancer.
Latest:
Long-Term Management of Patients with P53 AberrationsTreatment approaches to address mutations or deletions of chromosome 17p are needed due to the surfacing of point mutations, including TP53 aberrations in chronic lymphocytic leukemia.
Latest:
Multi-Stage Trial of Tagraxofusp Shows Frontline Efficacy in BPDCNAndrew A. Lane, MD, PhD, discusses the study design of a phase 1/2 trial of tagraxofusp-erzs for patients with blastic plasmacytoid dendritic cell neoplasms.
Latest:
Exploring the Importance of Finding a Molecular Target in Lung CancerBrendon Stiles, MD, discusses the current landscape for treating patients with metastatic lung cancer.
Latest:
Hot Topics of Discussion in the Management of Multiple MyelomaJens Hillengass, MD, discusses the key takeaways from his presentation at the 2020 National Comprehensive Cancer Network Virtual Congress: Hematologic Malignancies, in which he shared his insights on the diagnostic and staging criteria in multiple myeloma.
Latest:
Targeted Therapy, Immunotherapy Propel 10 Years of Progress in NSCLC"We should continue to see steady gains in new targets and improvements in our targeted therapies that make these options available for an ever-larger subgroup of patients with non–small cell lung cancer who can derive longer duration of benefit from additional lines of treatment," says H. Jack West, MD.
Latest:
Study Investigators Question the Rise of CRC in Young Adult PatientsAmir Khan, MD, discusses the possible reasons for the rising incidence of young adult patients with gastric cancer and colorectal cancer at the 2020 Gastrointestinal Cancers Symposium.
Latest:
Metastatic Endometrial Cancer: Future Directions in CareClosing out her discussion on the management of recurrent metastatic endometrial cancer, Bhavana Pothuri, MD, highlights ongoing clinical trials and novel treatment modalities.
Latest:
Polatuzumab Vedotin Plus R-CHOP May Improve Outcomes For DLBCL PatientsThomas Habermann, MD, discusses R-CHOP and how it can be improved upon as a treatment method for diffuse large B-cell lymphoma.
Latest:
Mirvetuximab Soravtansine Combination Improves Responses in Platinum-Agnostic Ovarian CancerLucy Gilbert, MD, MSc, discusses the findings from a phase 1b trial in which mirvetuximab soravtansine was combined with bevacizumab in recurrent, high-grade epithelial ovarian cancer regardless of platinum sensitivity.
Latest:
Research Ongoing for CAR T-Cell Therapy Axi-Cel in LymphomaSairah Ahmed, MD, discusses the continued investigations of axicabtagene ciloleucel, a chimeric antigen receptor T-cell therapy used in multiple types of lymphoma.
Latest:
CAR T Cell Therapy Shows Efficacy in B Cell Malignancies in Phase 1 TrialNirav N. Shah, MD, discusses bispecific anti-CD20 and anti-CD19 chimeric antigen receptor T cells in a phase 1 dose escalation and expansion trial for relapsed B cell malignancies.
Latest:
Comparing BIONIKK Data of Nivolumab With/Without Ipilimumab in mRCCYann-Alexandre Vano, MD, explains some of the findings from the phase 2 BIONIKK trial which evaluated nivolumab and ipilimumab in metastatic renal cell carcinoma.
Latest:
Anticipating Expanded Uses of Radiotherapy in Urothelial CarcinomaSophia Kamran, MD, discusses future roles that radiation oncology will play in combination with resection and targeted therapy in urothelial carcinoma.
